Apollomics reverses wind-up plans, provides operational update

Apollomics (APLM) announced the following company operational update: “The Company is currently conducting a global Phase 2 trial of APL-101, a promising targeted therapy that has seen positive results from clinical trials involving over 280 patients. With its late-stage clinical trial status and its history of positive patient developments, APL-101 represents a core investment of Apollomics that must be continued and further developed. On August 28, 2025, the Company, citing financial concerns, announced on Form 6-K that it “expected” to discontinue all clinical trial activities related to APL-101 and that it intended to seek shareholder approval to wind up the Company’s business. On September 3, 2025, the Company announced on Form 6-K that it had received $4.1 million PIPE investments from certain investors and appointed a new board of directors. The Current Board subsequently appointed a new management team, led by Hung-wen Chen as Chief Executive Officer, and Yi-kuei Chen as Chief Operating Officer, and Peter Lin, as Chief Financial Officer. With additional funding and new leadership, the Company has reversed its wind-up plans. Apollomics is continuing pre-existing operations and advancing the global development and commercialization of its intellectual property assets, such as APL-101. Although the former Board and management of Apollomics had announced that they “expect(ed)” to discontinue the SPARTA clinical trials associated with APL-101, there has been no stoppage, and under its current management, Apollomics aims to complete the clinical trials. Promptly after the September 3 Funding, the Company’s new management team began notifying its clinical research organizations and licensing partners about the leadership transition and continuity of operations and clinical trials. All contracts with the Company’s current CROs are fully paid and up to date. The Company has developed a comprehensive business plan for the next 12 months to ensure continued operations and strengthen its clinical development programs. Apollomics remains committed to the ongoing global multi-country, multi-center SPARTA clinical trial of APL-101. This program is important for maximizing the therapeutic potential of vebreltinib across multiple tumor types and to support regulatory submissions in the U.S., EU, and other major markets. In addition, the Company intends to leverage Chinese APL-101 approvals for MET-amplified NSCLC and GBM, obtained via its CRO and licensing partner in China, to pursue regulatory submissions in Southeast Asia, the Middle East, and other potential emerging markets outside of China. Apollomics currently has 12 full time employees. Apollomics expects total headcount to reach 15 by October 31, 2025i. Apollomics believes that the current headcount is sufficient to maintain clinical trials and operations. Apollomics also intends to reduce headcount in China and re-allocate headcount to the U.S. and Taiwan.”